Eli Lilly (NYSE: LLY) stock defied today's market downturn, rising 2.6% through 11:15 a.m. ET on the back of two positive ...

Eli Lilly (Lilly) has agreed to make a $10m upfront payment for full worldwide rights to San Diego-based Organovo Holdings’ ...

Eli Lilly has acquired Organovo’s lead asset, a clinical FXR agonist designed to treat inflammatory bowel disease (IBD), in a ...

Organovo Holdings, Inc. (Nasdaq:ONVO) (“Organovo” or the “Company”), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD) today ...

The deal with Lilly is a crucial boost for Organovo, which ended last year with just $1.2 million in cash and nearly $350 million in debt. Organovo FXR is a clinical drug program focused on farnesoid ...

Holdings announced that Eli Lilly (LLY) and Company will acquire Organovo’s FXR program, including its lead asset, FXR314.

Rare Disease Day, an annual gathering hosted by the FDA and National Institutes of Health, was postponed. Medicare spending on 10 diabetes drugs, including popular GLP-1s, more than quadrupled over a ...

US pharma major Eli Lilly has announced a deal with San Diego-based Organovo Holdings, a biotech focused on developing novel ...

has reached an agreement to sell its FXR program, including the lead asset FXR314, to pharmaceutical giant Eli Lilly and Company (NYSE:LLY), a $794 billion market cap company currently trading ...

Organovo shares are trading higher by 246% Tuesday morning. The company announced that Eli Lilly is set to acquire its FXR ...

Organovo today announced that Eli Lilly and Company (NYSE:LLY) ("Lilly") will acquire Organovo's FXR program, including its ...